Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.38 |
| ▸ | EDNRA | P25101 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10105631 | 0.82 | CHRNA7 (0.45) | CHRNA7EDNRALMNAMAPTCA12 | |
| SCHEMBL29354194 | 0.81 | TRPV4 (0.44) | TRPV4CA12CA1CA2CA4 | |
| SCHEMBL21144249 | 0.81 | TRPV4 (0.44) | TRPV4CA12CA1CA2CA4 | |
| SCHEMBL6179639 | 0.81 | CA12 (0.55) | CHRNA7EDNRALMNAMAPTCA12 | |
| SCHEMBL5002545 | 0.81 | FABP3 (0.40) | CHRNA7EDNRALMNAMAPTSMN1; SMN2 | |
| SCHEMBL5039363 | 0.79 | CA12 (0.53) | CHRNA7EDNRALMNAMAPTCA12 | |
| SCHEMBL12186143 | 0.79 | CHRNA7 (0.38) | CHRNA7EDNRAMAPTTSHRALDH1A1 | |
| Potassium SCHEMBL5039366 | 0.79 | CA12 (0.53) | CHRNA7EDNRALMNAMAPTCA12 | |
| SCHEMBL25836464 | 0.78 | ALDH1A1 (0.39) | EDNRALMNAMAPTSMN1; SMN2TSHR | |
| SCHEMBL25825555 | 0.77 | EDNRA (0.42) | CHRNA7EDNRALMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0897914-B1 | Process for the preparation of 2,5-disubstitued pyridines | HOFFMANN LA ROCHE (CH) | 2004-05-26 | — | — | EP | claimed |
| US-6080866-A | A CHEMICAL INTERMEDIATES FOR ENDOTHELIN RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2000-06-27 | — | — | US | claimed |
| EP-0897914-A1 | Process for the preparation of 2,5-disubstitued pyridines | F. HOFFMANN-LA ROCHE AG (CH) | 1999-02-24 | — | — | EP | claimed |
| EP-1554239-B1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-26 | — | — | EP | disclosed |
| US-7435815-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-10-14 | — | — | US | disclosed |
| US-7435815-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-10-14 | — | — | US | disclosed |
| US-7435815-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-10-14 | — | — | US | disclosed |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-18 | — | — | US | disclosed |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-18 | — | — | US | disclosed |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-18 | — | — | US | disclosed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | disclosed |
| US-5962682-A | Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists | HOFFMANN-LA ROCHE INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5958910-A | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5877193-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0897914-A1 | Process for the preparation of 2,5-disubstitued pyridines | F. HOFFMANN-LA ROCHE AG (CH) | 1999-02-24 | — | — | EP | disclosed |
| CN-1176101-A | N -(4 -aryl -thiazol -2 -yl) -sulphonamide derivatives and their use | HOFFMANN LA ROCHE (CH) | 1998-03-18 | — | — | CN | disclosed |
| EP-0819681-A2 | N-(4-Aryl-thiazol-2-yl)-sulfonamides and their use | F. HOFFMANN-LA ROCHE AG (CH) | 1998-01-21 | — | — | EP | disclosed |
| CN-1170405-A | Aryl and heteroaryl sulfonamide derivatives, their preparation and their use as endothelin antagonists | HOFFMANN LA ROCHE (CH) | 1998-01-14 | — | — | CN | disclosed |
| EP-0799206-A1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019455-A1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | HCRTR2, HCRTR1, GIPR | CHRNA7 128/4885EDNRA 280/4885LMNA 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.